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Mutations in the gene coding for the catalytic subunit of the mitochondrial DNA (mtDNA) polymerase g
(POLG1) have recently been described in patients with diverse clinical presentations, revealing a complex
relationship between genotype and phenotype in patients and their families. POLG1 was sequenced in patients
from different European diagnostic and research centres to define the phenotypic spectrum and advance
understanding of the recurrence risks. Mutations were identified in 38 cases, with the majority being sporadic
compound heterozygotes. Eighty-nine DNA sequence changes were identified, including 2 predicted to alter
a splice site, 1 predicted to cause a premature stop codon and 13 predicted to cause novel amino acid sub-
stitutions. The majority of children had a mutation in the linker region, often 1399G!A (A467T), and a
mutation affecting the polymerase domain. Others had mutations throughout the gene, and 11 had 3 or
more substitutions. The clinical presentation ranged from the neonatal period to late adult life, with an over-
lapping phenotypic spectrum from severe encephalopathy and liver failure to late-onset external ophthalmo-
plegia, ataxia, myopathy and isolated muscle pain or epilepsy. There was a strong gender bias in children, with
evidence of an environmental interaction with sodium valproate. POLG1 mutations cause an overlapping
clinical spectrum of disease with both dominant and recessive modes of inheritance. 1399G!A (A467T) is
common in children, but complete POLG1 sequencing is required to identify multiple mutations that can have
complex implications for genetic counselling.
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Introduction
The 16 569-base pair human mitochondrial genome is repli-
cated by the nuclear-encoded DNA polymerase g, pol g
(Clayton, 1982). Like other A-type polymerases, pol g has
both polymerase and 30!50 proofreading exonuclease activ-
ity, and is translated from 22 exons of the POLG1 gene on
chromosome 15q25 (Kaguni, 2004). The first pathogenic
mutations of POLG1 were identified in families with auto-
somal dominant chronic progressive external ophthalmople-
gia (adPEO, MIM 157640) associated with the accumulation
of multiple mitochondrial DNA (mtDNA) deletions in clini-
cally affected tissues (Van Goethem et al., 2001). Subsequent
work has shown compound heterozygous and homozygous
POLG1 mutations in recessive PEO (Van Goethem et al.,
2003b) and adult-onset cerebellar ataxia with multiple
mtDNA deletions (Van Goethem et al., 2004; Hakonen
et al., 2005; Winterthun et al., 2005). Recessive POLG1muta-
tions have recently been described in Alpers syndrome (also
called the Alpers–Huttenlocher syndrome, MIM 203700)
associated with mtDNA depletion (Naviaux and Nguyen,
2004; Davidzon et al., 2005; Ferrari et al., 2005). With the
recent description of parkinsonism and premature ovarian
failure in some dominant kindreds (Luoma et al., 2004), the
phenotypic spectrum associated with POLG1 mutations con-
tinues to expand (Del Bo et al., 2003; Gonzalez-Vioque et al.,
2006). At first sight, it appears that POLG1mutations cause a
growing number of totally discrete clinical categories. Here,
we present clinical and molecular findings in 38 previously
unreported patients with mutations in POLG1, demonstrat-
ing a continuous spectrum of disease, with both dominant
and recessive transmission.
Subjects, material and methods
Subjects
We studied a large collection of patients with clinical, biochemical
and molecular genetic evidence of mitochondrial disease from
several European research and diagnostic centres. Subjects were
identified from three main clinical groups.
(i) Sporadic and familial PEO with multiple mtDNA deletions.
Patients with (a) a clinical diagnosis of chronic PEO, (b) his-
tochemical evidence of mitochondrial disease, with cytochrome
c oxidase negative muscle fibres and/or ragged-red fibres in
greater proportions than would be expected for age-matched
healthy controls (Brierley et al., 1998), (c) multiple deletions
in skeletal muscle demonstrated by Southern blot or both
long-range polymerase chain reaction (PCR) and real-time
PCR (He et al., 2002).
(ii) Late-onset ataxia with multiple mtDNA deletions in skeletal
muscle. Patients with late-onset ataxia who fulfilled the
following criteria: (a) no evidence of a neoplastic, metabolic,
inflammatory and sporadic degenerative neurological disorder,
(b) negative molecular genetic testing for spinocerebellar
ataxia (SCA) 1, 2, 3, 6, 7, 17, dentatorubropallidoluysian
atrophy and Friedreich’s ataxia, (c) histochemical evidence
of mitochondrial disease, with cytochrome c oxidase negative
muscle fibres and/or ragged-red fibres in greater proportions
than would be expected for age-matched healthy controls
(Brierley et al., 1998), (d) multiple deletions in skeletal muscle
demonstrated with at least two of the following methods:
Southern blot, long-range PCR and real-time PCR (He et al.,
2002).
(iii) Alpers syndrome. Children with (a) refractory seizures,
(b) developmental delay, (c) liver failure, who had biochemical
evidence of mitochondrial dysfunction and/or depletion of
mtDNA in liver and/or skeletal muscle.
Molecular genetic methods
Nuclear gene screening
Total genomic DNA was extracted from whole blood and the entire
coding region and adjacent intronic regions of POLG1 were ampli-
fied by PCR and sequenced using a fluorescent chain terminating
sequencing kit (Applied Biosciences or Beckman Coulter Quickstart)
and a fluorescent DNA analyser (primers and conditions available
on request, Applied Biosciences 3100 or a Beckman Coulter CEQ
8000) and compared with the Genbank reference (accession number:
BC050559). Substitutions were confirmed by reverse sequencing.
C10ORF2 and ANT1 were also sequenced in seven individuals,
where complete sequencing of all three genes was standard practice
in one laboratory (indicated by an asterisk in Table 1, Genbank
accession numbers: AF292005 and BC061589). The frequency of
the novel sequence variants was determined in control chromosomes
by denaturing high-performance liquid chromatography (DHPLC,
Transgenomic Wave system, primers and conditions available on
request), and direct sequencing. Genotyping of the novel central
European variants was done by primer extension of multiplex
PCR products with the detection of the allele-specific extension
products by matrix-associated laser desorption/ionization time-
of-flight (MALDITOF; Sequenom, San Diego, CA, USA) mass spec-
trometry.
Statistical analysis
Allele frequencies were compared using Fisher’s exact test. Exact
95% confidence intervals were determined by the method of Clopper
and Pearson (Armitage et al., 2002).
Results
Clinical presentation
A wide range of phenotypes were observed in the patients
with POLG1 mutations, ranging from a fatal childhood
hepatoencephalopathy to a mild clinical syndrome affecting
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a single organ and presenting in adult life (Table 1). Of the 10
children who developed liver failure, the majority were male
(90%, Fisher’s exact P = 0.001) and presented in the first years
of life (mean 1.8 years, range 0.5–7 years) with an encephalo-
pathy and no family history. In five (50%), abnormal liver
function developed within weeks of commencing sodium
valproate for seizure control. Follow-up data were available
for 10 cases, with a large proportion (40%) dying before 2
years of age. Four of the five individuals who developed a
fluctuating encephalopathy without liver failure developed
symptoms in childhood (mean: 13.3 years, range: 4–32
years). All were male and none were treated with sodium
valproate. Stroke-like episodes and myoclonus were also
common in the group presenting in childhood.
The 19 patients with ptosis and PEO generally presented in
teenage years or adult life (mean: 36.1 years, range: 10–63).
Nine of these individuals had relevant family history, which
suggested dominant transmission in two. The majority of
the 19 individuals developed additional features including
a limb myopathy (79%), ataxia (42%), a peripheral neuro-
pathy (32%) or dysphagia (37%). Fifty-three per cent were
male (Fisher’s exact P = 1). Additional features in this
group included diabetes (11%), deafness (11%), young-onset
dementia (11%) and one patient with cardiomyopathy (5%).
No patients had parkinsonism. Of the individuals presenting
in adult life, only one patient had ataxia and a peripheral
neuropathy without PEO (5%). Additional presenting
features included isolated muscle pain and isolated epilepsy
as the only feature in two cases.
Overall, 13 subjects had a relevant family history (34%).
There was no relevant family history in 66% of cases.
Molecular genetics
We identified 89 changes from the reference sequence,
including 2 novel predicted splice-site mutations, 1 predicted
to introduce a premature stop codon and 13 predicted to alter
the amino acid sequence (Fig. 1, Tables 1 and 2). For clarity,
each mutation is presented in terms of the predicted amino
acid substitution, with the exception of predicted splice-site
mutations.
Heterozygous alleles were found in four individuals with
a family history consistent with dominant transmission,
including the previously described mutations W312R, and
T251I-p587L in cis. The only novel dominant mutation
was G517V mutation found in three affected individuals in
three generations of one family. The remaining 34 subjects
had at least two mutated alleles. Nine were homozygous
(26.5% of the recessive cases), including all three consangui-
neous children. Two individuals had mutations predicted to
alter splice-sites (2.2% of substitutions, 5.3% of subjects), and
one a novel stop-codon mutation (L965X). A467T was found
in 12 of the 19 who presented in childhood (63.2%), and
was homozygous in 4 (21.1% of children). Four substitutions
were identified in six individuals (each with two pairs
in cis confirmed by direct sequencing of the parents). The
allele frequency corresponding to T251I, A467T, V1106I,
E1143G and the novel substitutions is shown in Table 2.
Sequencing of C10ORF2 and ANT1 in seven individuals
did not identify any changes from the reference sequence
(Table 1, individuals indicated by an asterisk).
Discussion
Clinical features
Although our method of case ascertainment led to the iden-
tification of three prominent clinical groups, key individuals
demonstrate the overlapping phenotypic spectrum associated
with POLG1 mutations (Table 1). Most patients with a fluc-
tuating encephalopathy presented in childhood, but one
adult presented in his third decade with a rapidly progressive
fatal multi-system disorder with PEO, and one adult devel-
oped a slowly progressive dementing illness. Most adults with
POLG1 mutations developed PEO and a limb myopathy,
often in association with ataxia and an axonal sensorimotor
peripheral neuropathy [similar to the original description of
sensory ataxic neuropathy with gastrointestinal dysmotility
and ophthalmoplegia, SANDO (Fadic et al., 1997)], but some
presented with myopathy or ataxia without PEO. Although
we did identify cardiomyopathy in two subjects and a
cardiac conduction defect in one, none had a pigmentary
retinopathy. We also observed isolated mild phenotypes
broadening the clinical spectrum associated with POLG1
mutations, including epilepsy as a presenting feature in
two cases. Isolated ataxia with neuropathy was uncommon
in this cohort, but myoclonus was noted especially in child-
hood onset cases. Parkinsonism was also uncommon, possi-
bly because we did not find dominant POLG1 polymerase
domain mutations, which are the mutations that have been
associated with parkinsonism to date (Luoma et al., 2004).
POLG1 mutations clearly do not exert their effect in iso-
lation. The vast majority of severe childhood presentations
were in boys. Gender bias is well recognized in other mito-
chondrial disorders, and recent evidence supports the role of
additional nuclear genetic modifier loci interacting with the
primary defect (Carelli et al., 2003; Hudson et al., 2005). It is
intriguing that later-onset POLG1 phenotypes are less sus-
ceptible to this bias, equally affecting men and women. In
four infants the liver dysfunction began after treatment with
sodium valproate, and the children with isolated encephalo-
pathy were not exposed to this drug, nor were the adult cases.
This demonstrates the potential effect of environmental fac-
tors modulating the phenotypic spectrum of the disorder,
and suggests that this drug should be used with caution,
or avoided in this group of patients. It is tempting to spec-
ulate that gender and environmental factors are more likely
to influence the clinical expression of the more severe
molecular defects presenting in childhood. Further clinical
and functional studies will hopefully clarify the underlying
mechanisms.
1676 Brain (2006), 129, 1674–1684 R. Horvath et al.
T
a
b
le
1
C
lin
ic
al
p
h
en
o
ty
p
e
an
d
PO
LG
1
su
b
st
it
u
ti
o
n
s
A
ge
at
o
n
se
t
(y
ea
rs
)
C
u
rr
en
t
ag
e
(y
ea
rs
)a
Se
x
Fa
m
ily
h
is
to
ry
P
ri
m
ar
y
cl
in
ic
al
fe
at
u
re
s
O
th
er
fe
at
u
re
s
PO
LG
1
su
b
st
it
u
ti
o
n
se
Liver
b
Encephalopathy
PEO
Ataxia
Dysphagia
Neuropathy
c
Myopathy
d
cD
N
A
su
b
st
it
u
ti
o
n
P
re
d
ic
te
d
am
in
o
ac
id
ch
an
ge
D
o
m
ai
n
E
x
o
Li
n
k
P
o
l
G
ro
u
p
1
:
Li
ve
r
an
d
en
ce
p
h
al
o
p
at
h
y
0
.5
1
.3
D
M
N
il
+
+
C
ar
d
io
m
yo
p
at
h
y
1
3
9
9
G
!
A
A
4
6
7
T
3
5
7
3
G
!
T
K
1
1
9
1
N
+
+
0
.5
1
.3
D
M
N
il
+
+
9
2
6
G
!
A
R
3
0
9
H
+
1
8
8
0
G
!
A
R
6
2
7
Q
+
0
.6
1
D
F
N
il
+
+
1
3
9
9
G
!
A
A
4
6
7
T
2
5
4
2
G
!
A
G
8
4
8
S
+
+
0
.8
1
D
M
E
p
ile
p
sy
:
fa
th
er
+
+
2
2
0
9
G
!
C
G
7
3
7
R
an
d
co
u
si
n
(v
)
2
3
0
0
C
!
A
A
7
6
7
D
+
+
1
1
.4
D
M
N
il
+
+
1
3
9
9
G
!
A
A
4
6
7
T
IV
S1
5
-9
_
1
2
D
el
–
+
+
1
.2
5
2
.5
M
N
il
+
+
C
o
rt
ic
al
b
lin
d
n
es
s
1
3
9
9
G
!
A
A
4
6
7
T
IV
S2
1
+
1
T
!
C
–
+
+
1
.5
2
M
N
il
+
+
C
o
rt
ic
al
b
lin
d
n
es
s
1
3
9
9
G
!
A
A
4
6
7
T
(v
)
2
7
4
0
A
!
C
T
9
1
4
P
+
+
2
9
M
C
o
n
sa
n
gu
in
eo
u
s
+
+
M
yo
cl
o
n
u
s
ac
h
al
as
ia
3
2
8
6
C
!
T
3
7
0
8
G
!
T
*
R
1
0
9
6
C
Q
1
2
3
6
H
+
+
(v
)
3
2
8
6
C
!
T
3
7
0
8
G
!
T
R
1
0
9
6
C
Q
1
2
3
6
H
+
+
2
.5
3
M
N
il
+
+
1
3
9
9
G
!
A
2
6
5
3
A
!
T
*
A
4
6
7
T
T
8
8
5
S
(v
)
2
6
3
7
T
!
G
3
4
2
8
A
!
G
Q
8
7
9
H
E
1
1
4
3
G
+
+
+
+
7
8
D
M
N
il
+
+
SL
E
se
iz
u
re
s
1
8
8
0
G
!
A
R
6
2
7
Q
+
+
(v
)
3
2
8
7
G
!
A
R
1
0
9
6
H
G
ro
u
p
2
:
E
n
ce
p
h
al
o
p
at
h
y
4
8
M
N
il
+
M
yo
cl
o
n
u
s
an
d
SL
E
1
3
9
9
G
!
A
A
4
6
7
T
+
+
2
7
4
0
A
!
C
T
9
1
4
P
7
.5
7
.5
M
N
il
+
+
1
3
9
9
G
!
A
A
4
6
7
T
+
+
1
3
9
9
G
!
A
A
4
6
7
T
+
+
8
8
M
C
o
n
sa
n
gu
in
eo
u
s
+
SL
E
1
3
9
9
G
!
A
A
4
6
7
T
1
3
9
9
G
!
A
A
4
6
7
T
+
+
1
5
1
7
M
n
/a
+
M
yo
cl
o
n
u
s
1
3
9
9
G
!
A
*
A
4
6
7
T
1
3
9
9
G
!
A
A
4
6
7
T
+
+
G
ro
u
p
3
:
P
E
O
6
o
th
er
fe
at
u
re
s
n
/a
5
6
F
N
il
+
+
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
+
+
+
+
n
/a
3
5
F
N
il
+
+
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
3
3
1
6
G
!
A
V
1
1
0
6
I
+
+
+
n
/a
n
/a
n
/a
Si
b
+
+
+
+
+
D
ia
b
et
es
1
3
9
9
G
!
A
*
A
4
6
7
T
Phenotype of POLG1 mutations Brain (2006), 129, 1674–1684 1677
2
2
4
3
G
!
C
W
7
4
8
S
+
+
1
0
1
4
F
N
il
+
+
9
2
4
G
!
C
Q
3
0
8
H
2
7
4
0
A
!
C
3
4
9
0
T
!
A
T
9
1
4
P
F1
1
6
4
I
+
+
+
1
5
4
8
M
Si
st
er
w
it
h
A
lp
er
s
+
+
+
+
+
D
em
en
ti
a
1
3
9
9
G
!
A
A
4
6
7
T
3
4
2
8
A
!
G
E
1
1
4
3
G
+
+
2
5
5
3
M
C
o
n
sa
n
gu
in
eo
u
s
+
+
+
T
h
yr
o
id
d
is
ea
se
1
9
4
3
C
!
G
P6
4
8
R
1
9
4
3
C
!
G
P6
4
8
R
+
+
2
5
5
0
M
N
il
+
+
+
+
P
sy
ch
o
si
s
d
em
en
ti
a
1
2
9
8
C
!
G
*
S4
3
3
C
3
4
2
8
A
!
G
E
1
1
4
3
G
+
+
2
6
4
5
F
N
il
+
+
+
M
yo
cl
o
n
u
s
ep
ile
p
sy
1
8
8
0
G
!
A
3
7
0
8
G
!
T
R
6
2
7
Q
Q
1
2
3
6
H
2
8
9
4
T
!
G
3
4
2
8
A
!
G
L9
6
5
X
E
1
1
4
3
G
+
+
+
+
3
2
4
1
D
M
A
ff
ec
te
d
si
b
lin
g
+
+
+
+
+
+
C
ar
d
io
m
yo
p
at
h
y
1
3
9
9
G
!
A
A
4
6
7
T
H
ea
ri
n
g
lo
ss
1
8
7
9
C
!
T
R
6
2
7
W
+
+
3
4
4
9
M
A
ff
ec
te
d
si
b
lin
g
+
+
+
+
+
D
ia
b
et
es
1
3
9
9
G
!
A
*
A
4
6
7
T
2
2
4
3
G
!
C
W
7
4
8
S
+
+
3
7
6
2
M
N
il
+
+
+
9
3
4
T
!
C
W
3
1
2
R
1
7
2
0
C
!
T
R
5
7
4
W
+
+
3
9
5
4
M
Si
b
+
+
+
H
ea
ri
n
g
lo
ss
1
3
9
9
G
!
A
A
4
6
7
T
1
8
7
9
C
!
T
R
6
2
7
W
+
+
4
5
7
4
F
Si
b
+
+
+
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
9
1
1
T
!
G
L3
0
4
R
+
+
+
4
8
5
6
M
N
il
+
6
7
9
C
!
T
R
2
2
7
W
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
+
+
+
5
3
5
5
F
N
il
+
+
1
9
4
3
C
!
G
P
6
4
8
R
3
2
8
6
C
!
T
R
1
0
9
6
C
+
+
6
0
6
2
F
P
to
si
s:
fa
th
er
+
9
3
4
T
!
C
*
W
3
1
2
R
+
6
0
6
8
M
A
ff
ec
te
d
si
b
lin
g
+
+
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
9
1
1
T
!
G
L3
0
4
R
+
+
+
6
2
7
0
F
N
il
+
+
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
+
+
+
+
6
3
7
4
M
N
il
+
+
C
h
ro
n
ic
b
ro
n
ch
it
is
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
+
+
+
+
G
ro
u
p
4
:
O
th
er
4
8
5
8
M
P
o
ss
ib
le
d
o
m
in
an
t
+
H
ea
rt
b
lo
ck
,
m
u
sc
le
p
ai
n
7
5
2
C
!
T
1
7
6
0
C
!
T
T
2
5
1
I
P
5
8
7
L
+
+
4
2
6
F
Fa
th
er
an
d
d
au
gh
te
r
+
+
E
x
er
ci
se
in
to
le
ra
n
ce
1
5
5
0
G
!
T
G
5
1
7
V
+
+
3
4
2
8
A
!
G
E
1
1
4
3
G
5
0
5
8
M
D
au
gh
te
r
an
d
gr
an
d
d
au
gh
te
r
+
1
5
5
0
G
!
T
G
5
1
7
V
+
7
8
F
M
o
th
er
an
d
gr
an
d
fa
th
er
E
p
ile
p
sy
1
5
5
0
G
!
T
G
5
1
7
V
+
1
5
2
0
F
N
il
E
p
ile
p
sy
1
3
9
9
G
!
A
A
4
6
7
T
1
3
9
9
G
!
A
A
4
6
7
T
+
+
P
at
ie
n
ts
ar
e
ar
ra
n
ge
d
in
to
fo
u
r
gr
o
u
p
s.
W
it
h
in
ea
ch
gr
o
u
p
th
e
p
at
ie
n
ts
ar
e
o
rd
er
ed
b
y
in
cr
ea
si
n
g
ag
e
o
fo
n
se
t
to
ill
u
st
ra
te
th
e
ag
e
sp
ec
tr
u
m
an
d
p
h
en
o
ty
p
es
as
so
ci
at
ed
w
it
h
th
e
d
iff
er
en
t
ag
es
at
p
re
se
n
ta
ti
o
n
.G
ro
u
p
1
=
en
ce
p
h
al
o
p
at
h
y
w
it
h
liv
er
fa
ilu
re
(A
lp
er
s–
H
u
tt
en
lo
ch
er
sy
n
d
ro
m
e)
.G
ro
u
p
2
=
ch
ild
h
o
o
d
en
ce
p
h
al
o
p
at
h
y
w
it
h
o
u
t
cl
in
ic
al
ev
id
en
ce
o
fl
iv
er
in
vo
lv
em
en
t.
G
ro
u
p
3
=
p
at
ie
n
ts
w
it
h
P
E
O
6
ad
d
it
io
n
al
fe
at
u
re
s.
G
ro
u
p
4
=
o
th
er
cl
in
ic
al
p
re
se
n
ta
ti
o
n
s.
E
x
o
=
ex
o
n
u
cl
ea
se
d
o
m
ai
n
,
lin
k
=
lin
ke
r
d
o
m
ai
n
,
p
o
l
=
p
o
ly
m
er
as
e
d
o
m
ai
n
(s
ee
Fi
g.
1
),
C
C
=
co
rp
u
s
ca
llo
su
m
,
P
E
O
=
p
ro
gr
es
si
ve
ex
te
rn
al
o
p
h
th
al
m
o
p
le
gi
a,
SL
E
=
st
ro
ke
-l
ik
e
ep
is
o
d
es
,
n
/a
=
n
o
t
av
ai
la
b
le
.
C
1
0
O
R
F2
an
d
A
N
T
1
al
so
se
q
u
en
ce
d
in
in
d
iv
id
u
al
s
in
d
ic
at
ed
b
y
as
te
ri
sk
(*
).
a D
=
ag
e
o
f
d
ea
th
;
b
(v
)
=
d
et
er
io
ra
ti
o
n
af
te
r
st
ar
ti
n
g
so
d
iu
m
va
lp
ro
at
e;
c a
x
o
n
al
se
n
so
r-
m
o
to
r
n
eu
ro
p
at
h
y;
d
p
ro
x
im
al
m
yo
p
at
h
y;
e
n
o
ve
l
su
b
st
it
u
ti
o
n
s
in
it
al
ic
s.
1678 Brain (2006), 129, 1674–1684 R. Horvath et al.
POLG1 mutations
Following the identification of the first pathogenic POLG1
mutations (Van Goethem et al., 2001), a range of nucleotide
substitutions have been described in patients and control
subjects (http://dir-apps.niehs.nih.gov/polg/ and http://
www.ncbi.nlm.nih.gov/SNP/). This presents a diagnostic
challenge: in individual patients it can be difficult to decide
which substitutions are directly responsible for the disease,
and which are polymorphic variants. The possibility that
frequent polymorphic genetic variants modify the phenotype
further complicates the situation (Hisama et al., 2005). We
considered a nucleotide substitution to be pathogenic when
(i) it was predicted to alter a conserved amino acid in a
functionally relevant site of pol g; (ii) it was close to other
established pathogenic POLG1 mutations; (iii) compound
heterozygous mutations were never homozygous in control
subjects; (iv) dominant mutations were never found in con-
trol subjects. This study has shown that the population fre-
quency of heterozygous carriers varies throughout Europe
(Table 2). Given the polymorphic nature of POLG1, studying
a large, ethnically matched control group is of fundamental
importance. Final confirmation of pathogenicity is only pos-
sible when the same substitution segregates with disease in
different families, and the proposed mechanism is supported
by functional data.
We identified 16 novel mutations. These were either
not detected in large control groups from corresponding
geographical regions, or they were extremely rare (<0.5%,
Table 2). Conservation tables showing the position of the
predicted amino acid substitutions are shown in the online
supplement.
Novel mutations predicted to
truncate pol g
The two predicted to alter splice sites (IVS15-9-c.2485
Del12bp, IVS21+1T!C) were compound heterozygotes
with previously reported pathogenic mutations. The only
stop-codon mutation (L965X) was found in a compound
heterozygote with a previously described recessive mutation
[R627Q (Luoma et al., 2005)] and is predicted to remove part
of the catalytic domain of pol g. A similar stop-codon muta-
tion (E873X) was shown to cause nonsense associated alter-
native splicing and nonsense mediated decay with Alpers
syndrome in a compound heterozygote with A467T (Chan
et al., 2005a).
Novel recessive missense mutations
Of the remaining 13 novel missense mutations, T914P was
found in three unrelated compound heterozygotes. This
mutation alters a conserved amino acid residue and is
close to a published pathogenic mutation (G923D) in the
polymerase domain (Lamantea et al., 2002). P648R was
homozygous in one consanguineous patient with PEO, ataxia
and a neuropathy, and in a compound heterozygote with
a previously identified pathogenic mutation. P648R alters a
conserved residue in the linker region of pol g, close to the
previously published R627W and R627Q (Van Goethem et al.,
2003b; Luoma et al., 2005). The substitutions G737R, A767D,
Q879H, T885S and K1191N were also found in compound
heterozygotes, altered conserved residues, and were close to
published pathogenic mutations in the polymerase domain
[W748S, R853W, N864S, A889T, and D1184N (Agostino
et al., 2003; Filosto et al., 2003; Van Goethem et al., 2003c;
Van Goethem et al., 2004; Gonzalez-Vioque et al., 2006)]. The
R1096H substitution affects the same codon as the previously
reported R1096C (Agostino et al., 2003). S433C and R574W
were found in different compound heterozygotes with a pre-
viously published substitution. Both are close to previously
reported recessive mutations in the linker region [G431V
(Agostino et al., 2003); R562Q and R579W (Di Fonzo et al.,
2003; Filosto et al., 2003)]. One mutation in the exonuclease
2 3 4 5 6 7 8 9 10 1112 13 14 1516 17 18 19 20 21 22 23
A
B 467 885 1143737308
I II III A B C
Exonuclease Domain Polymerase Domain
648
Linker region
Fig. 1 POLG1 substitutions in the 38 patients. Location of intronic/splice site variations (A) and amino acid substitutions (B). Red = novel
substitutions; blue = previously described substitutions. Numbers above are examples of specific sites to illustrate the position of
the amino acid residues. The exonuclease domain extends from amino acid residue 1–418. The polymerase domain extends
from amino acid residue 756–1239. The linker region lies between amino acid residues 418 and 756 (Nguyen et al., 2005).
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domain (Q308H) was also in a compound heterozygote, and
is adjacent to a previously reported recessive mutation
[R309L (Lamantea et al., 2002)].
Dominant mutations
One novel heterozygous linker-region mutation was found
(G517V) in one family with clear evidence of dominant trans-
mission. Intriguingly, most dominant mutations reported
to date affect the polymerase domain (Luoma et al., 2004;
Van Goethem et al., 2004). In two families with dominant
transmission, previously published recessive alleles [W312R
and T251I-P587L (Lamantea et al., 2002; Agostino et al.,
2003)] were the only POLG1 mutations identified.
Relationship between genotype and
phenotype
Our observations confirm that pathogenic mutations in
POLG1 are scattered throughout the coding region (Fig. 1).
Although there is not a strict genotype–phenotype relation-
ship, a pattern is emerging (Table 1). Most cases with a severe
disease onset in childhood are associated with at least one
mutation in the linker region, and one in the polymerase
domain (Table 1). In contrast, in this series, exonuclease
domain mutations are more commonly found in patients
presenting in teenage or adult life. However, onset in
childhood has been previously noted for W748S homo-
zygotes (Hakonen et al., 2005). Finally, all but one of the
patients with two linker-region mutations presented in
adult life. It should be noted, however, that the conventional
subdivision of the POLG1 gene into three distinct regions
implies a strict genotype–phenotype relationship at the bio-
chemical level. This appears not to be the case, because
mutations in the linker region can affect catalytic efficiency
of pol g (Chan et al., 2005b).
58.9% of the childhood-onset cases harboured the A467T
linker-region mutation, but only 21.1% of the remaining
cases haboured A467T. In this study, A467T was found in
0.69% of British control alleles, providing a reservoir for
recessive disease. In contrast, A467T was found in 0.17%
of Finnish control alleles, 0.19% of 1066 German control
alleles, but not in 674 Italian control chromosomes, demon-
strating geographic differences in the carrier frequency
around Europe (Table 2). It is not clear why more
childhood-onset cases are associated with A467T than
adult-onset cases. Intriguingly, the four individuals homozy-
gous for A467T had a milder phenotype when compared with
compound heterozygotes with the same mutation. This is
surprising given recent in vitro data demonstrating only
5% polymerase activity with the A467T mutant protein
(Chan et al., 2005b; Luoma et al., 2005), suggesting that
other factors contribute to the phenotypic variability, as
for the W748S mutation (Hakonen et al., 2005). Further
observations on a larger cohort are needed to substantiate
this finding. Recent clinical studies highlight the potential
role of A467T in late-onset mild ptosis and PEO (Luoma
et al., 2005). Given the frequency of this mutation in
Table 2 Allele frequencies in control subjects
Nucleotide
change
Predicted
amino acid
substitution
Geographic
origin of the
patients*
Allele frequency in control subjects
British German Italian Finnish
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
752T!C T251I C, I, F 5/450** 1.11 (0.36–2.57)
924G!C Q308H I 0/200 0 (0–1.49)
1399A!G A467T C, I, UK 3/432 0.69 (0.14–2.02) 2/1066 0.19 (0.02– 0.73) 0/674 0 (0–0.44) 1/602 0.17
(0–0.92)
1550G!T G517V C 1/672 0.15 (0–0.83)
1720C!T R574W I 0/200 0 (0–1.49)
1943C!G P648R I 0/200 0 0–1.49)
2209G!C G737R C 2/666 0.3 (0.04–1.08)
2300C!A A767D C 0/678 0 (0–0.44)
2637G!A Q879H UK 0/192 0 (0–1.09)
2653A!T T885S UK 0/192 0 (0–1.09)
2740A!C T914P C, I 0/664 0 (0– 0.45) 0/200 0 (0–1.49)
3316G!A V1106I I 0/500 0 (0–0.60)
3428A!G E1143G C, UK 4/192 2.08 (0.57–5.25) 8/300 2.67
(1.16–5.19)
3490T!A F1164I I 0/200 0 (0–1.49)
3573G!T K1191N C 0/664 0 (0– 0.45)
IVS21+1T!C – C 0/666 0 (0– 0.45)
IVS15-9_12Del – C 1/666 0.15 (0–0.83)
n = number of chromosomes with the allele; N = total number of chromosomes screened. 95% CI = exact 95% confidence interval.
*C = central European, F = Finnish, I = Italian, UK = United Kingdom; ** = P587L was found in all Italian cases with T251I.
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the general population, it is likely that many cases remain
undiagnosed.
In contrast, we only identified E1143G in five patients.
E1143G is found at a higher frequency than A467T in the
general population [2.1% of British controls in this study,
3.3% of Belgians (Van Goethem et al., 2001), 2.1% of Finns
(Van Goethem et al., 2004) and 2.9% of the North American
population (http://www.ncbi.nlm.nih.gov/SNP/)]. However,
E1143G homozygotes have never been described in patients
with disease, although we have detected them in control
subjects (Suomalainen A, Ahola S, Luoma P, unpublished).
In contrast, the frequency of E1143G in our patient cohort
was significantly greater than controls (Fisher’s exact P =
0.007). In addition, in the three-generation family with
G517V the clinical presentation of the heterozygous carriers
was very variable (epilepsy, neuropathy and myopathy, mild
neuropathy). The most severe phenotype was observed in the
mother, who also carried the E1143G substitution on the
other allele. When taken together, this suggests that, on its
own, E1143G is not sufficient to cause disease (either in a
homozygous or heterozygous state), but it can cause disease
when in combination with a different compound heterozy-
gous mutation. It may also act as a phenotypic modifier
through an interaction with other mutations (Hisama et al.,
2005).
Multiple mutations in POLG1
In 11 individuals we identified more than 2 substitutions (see
Table 1, where mutations in cis are shown on the same line).
Seven of these individuals harboured T251I and P587L in cis,
as compound heterozygotes with other putative pathogenic
mutations as described previously (Di Fonzo et al., 2003;
Ferrari et al., 2005). In two previous studies, T251I was
reported in compound heterozygotes without P587L
(Lamantea et al., 2002; Di Fonzo et al., 2003). However, in
one individual, this was a technical artefact, and further ana-
lysis identified P587L (Lamantea and Zeviani, 2004). More-
over, all five of the Italian carriers of T251I detected in this
study also had P587L (Table 2). Thus, in the vast majority of
cases reported to date, T251I and P587L have been described
in cis, and it is currently not possible to determine whether
T251I or P587L is the primary pathogenic allele, or whether
both substitutions are required to cause disease in these
patients. On the other hand, P587L was recently described
in a compound heterozygote with R853W presenting with
PEO and ptosis without T251I (Gonzalez-Vioque et al., 2006).
On balance, it is therefore likely that P587L is the pathogenic
allele, but in most affected individuals the allele is also
transmitted with T251I. The functional significance of the
T251I substitution therefore remains uncertain at present.
T251I-P587L was detected in 1.1% of Italian control chro-
mosomes, thus providing a reservoir for recessive disease
in this population.
One individual had the novel mutation Q308H as com-
pound heterozygote with T914P and F1164I in cis. Since we
also identified two compound heterozygotes with T914P in
the absence of F1164I, this suggests that T914P is the primary
pathogenic mutation in this case, and not F1164I. We also
identified homozygous substitution Q1236H in a consangui-
neous child in cis with the previously published pathogenic
mutation (R1096C) (Agostino et al., 2003). Q1236H has been
found in patients with PEO (Di Fonzo et al., 2003), and up to
4% of control subjects (http://www.ncbi.nlm.nih.gov/SNP),
and 15% of Finns (Luoma et al., 2005), suggesting that it is a
polymorphism with no functional consequences. It is likely
that R1096C is primarily pathogenic in this individual.
Finally, in one boy we found four substitutions. Segrega-
tion analysis confirmed that A467T was in cis with the novel
mutation T885S (from the mother), and Q879H was in cis
with E1143G (from the father). Although tempting to spec-
ulate that the four mutations act synergistically to cause the
severe phenotype in this individual, he was not the most
severely affected case in our series, with other individuals
having only two compound heterozygous mutations. On
the other hand, given emerging data from functional
(Chan et al., 2005) and clinical studies (Hisama et al.,
2005), it is clear that A467T contributes directly to the
pathogenesis, and E1143G may modify the phenotype.
Mutations in C10ORF2 and ANT1
Recently, a patient/family with PEO transmitted both a muta-
tion in POLG1 (G848S) and C10ORF (R334Q), and it was
suggested that the two mutated alleles interacted to cause the
disease (Van Goethem et al., 2003a). We therefore sequenced
C10ORF2 and ANT1 in seven of the individuals described
here. No substitutions were identified, demonstrating that
co-mutation is not common. Moreover, we have also
identified the R334Q C10ORF2 mutation in a family with
dominant PEO with no associated mutation in POLG1,
demonstrating that R334Q is primarily pathogenic on its
own, and questioning the role of the POLG1 mutation in
the earlier report. Thus, clear-cut digenic interaction of
POLG1 and C10ORF2 has yet to be demonstrated.
Conclusions—diagnosis and clinical
genetic implications
Identifying which individuals to screen for POLG1mutations
can be difficult. The majority of subjects in this study had no
relevant family history, including those with limited pheno-
types, indicating the importance of considering POLG1
mutations in a broad range of sporadic neuromuscular
diseases. All of the cases in this study either had clear bio-
chemical evidence of mitochondrial dysfunction in muscle,
liver or fibroblasts, and/or a secondary defect of mtDNA in
affected tissues, but this is not always the case. POLG1 muta-
tions have been described in adults with normal muscle
histochemistry and a normal Southern blot of muscle
mtDNA (Van Goethem et al., 2004). However, retrospective
analysis of the literature and the cases presented here confirm
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that a sensitive PCR-based assay detected a small amount
of deleted mtDNA in all POLG1 patients presenting in
adult life (Van Goethem et al., 2003c; Luoma et al., 2005).
On the basis of the available data, if muscle is available,
mtDNA PCR analysis is an effective primary screening
method to identify patients for POLG1 sequencing. It should,
however, be noted that low levels of deleted mtDNA also
occur in healthy aged individuals. The muscle mtDNA
screening approach is therefore sensitive, but not specific.
Selecting which patients to screen ultimately relies on
clinical suspicion, and hence the importance of our careful
documentation of the relationship between genotype and
phenotype. Our current diagnostic approach is outlined
in Fig. 2.
ADULT
Presenting
>16 yrs of age
CHILD
Presenting
<16 yrs of age
Classical 
Alpers
syndrome?
Screen for
A467T
(blood DNA)
Sequence
POLG1 
(blood DNA)
MUSCLE BIOPSY
•Quantify mtDNA
(Southern blot or real-time PCR)
PEO / unexplained multi-system neurological disorder
or 
Isolated neurological disorder with a relevant family history
MUSCLE BIOPSY
Muscle histochemistry
•MtDNA deletions
•Quantify mtDNA
(long-range PCR plus Southern blot or real-time PCR)
Strong 
clinical 
suspicion?
YES NO
Unexplained encephalopathy 
or multi-system neurological disorder
Homozygous 
For A467T ?
(blood DNA)
NO
Multiple deletions 
or depletion
YES
-ve
+ve
-ve
+ve
Fig. 2 Algorithm for the investigation of suspected POLG1 mutations. Children (presenting at <16 years of age) with an unexplained
encephalopathy or multi-system neurological disorder should be investigated for a possible POLG1 mutation. If the child has classical
Alpers–Huttenlocher syndrome (encephalopathy with refractory seizures, developmental delay and liver failure), then a blood sample
should be screened for the 1399G!A (A467T) substitution. If the patient is heterozygous for A467T, then POLG1 should be sequenced in
blood DNA. If the patient is homozygous for A467T, this confirms the diagnosis. It would be prudent to sequence POLG1 in a subject
homozygous for A467T to determine whether there are additional mutations/substitutions that could influence genetic counselling.
If the child does not have classical Alpers syndrome, then a muscle biopsy is indicated, and muscle mtDNA should be quantified by Southern
blot or real-time PCR. POLG1 should be sequenced if there is evidence of mtDNA depletion. It is possible to quantify mtDNA in other
affected tissues (e.g. a liver biopsy or post-mortem brain tissue), but the results are often difficult to interpret because of a lack of
control data. Adults (presenting >16 years of age) should have a muscle biopsy if they have PEO, an unexplained multi-system neurological
disorder, or an isolated neurological disorder (such as ataxia, epilepsy or myopathy) with a family history suggesting mitochondrial disease.
Muscle mtDNA should be analysed for mtDNA deletions and mtDNA depletion. Long-range PCR can be used to screen for mtDNA
deletions but the preferential amplification of smaller deleted mtDNA molecules means that this technique is not quantitative. mtDNA
deletions develop in skeletal muscle as part of normal ageing. The presence of significant levels (>5%) of deleted mtDNA should therefore
be confirmed by Southern blot or real-time PCR. POLG1 should be sequenced in patients with significant depletion or multiple deletions of
mtDNA. Some patients with POLG1 mutations have normal skeletal muscle histochemistry and no evidence of a secondary mtDNA
abnormality in skeletal muscle (Van Goethem et al., 2004). If there is therefore a strong clinical suspicion of POLG1 related disease
(such as PEO, or a family history consistent with the disorder), then POLG1 should be sequenced in these individuals when the muscle
histochemistry and muscle mtDNA analysis is normal. POLG1 sequencing is commercially available (March 2003). Details can be found on
www.genetests.org and www.ednal.com. If POLG1 sequencing is negative, then other nuclear genes should be screened, including C10ORF2
and ANT1. +ve = positive. ve = negative.
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Collecting clinical and molecular data from 38 new cases
with POLG1 mutations highlights the complexity of genetic
counselling for this group. This is illustrated by linker-region
mutation A467T, which can cause a severe fatal childhood
encephalopathy as a compound heterozygote with a mutation
in the polymerase domain, but possibly a milder phenotype
in homozygotes. In one juvenile homozygous individual
A467T/A467T, isolated epilepsy was the only feature at
20 years of age. This has been observed before in subjects
with a homozygous linker-region mutation, but additional
features developed later in life (Hakonen et al., 2005). A467T
was found in control subjects in some populations, and the
parents of the affected children in this study were clinically
normal. However, clinical genetic and functional studies
suggest that A467T can also behave as a dominant mutation
causing a mild phenotype of late-onset ptosis (Luoma et al.,
2005). This observation, coupled with emerging evidence that
POLG1 contains putative genetic modifiers, which are
common in the background population (Hakonen et al.,
2005), makes genetic counselling difficult for families with
more than two substitutions. Counselling the family with
four POLG1 mutations will be particularly challenging.
Further clinical and functional studies will help resolve
these issues.
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